AstraZeneca Pharma India Limited (BOM:506820)
India · Delayed Price · Currency is INR 8,984.05
+188.65 (2.14%)
At close: May 26, 2026
AstraZeneca Pharma India Revenue
In the fiscal year ending March 31, 2026, AstraZeneca Pharma India had annual revenue of 23.04B INR with 34.25% growth. AstraZeneca Pharma India had revenue of 5.85B in the quarter ending March 31, 2026, with 21.66% growth.
Revenue
23.04B
Revenue Growth
+34.25%
P/S Ratio
9.39
Revenue / Employee
38.40M
Employees
600
Market Cap
216.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 23.04B | 5.88B | 34.25% |
| Mar 31, 2025 | 17.16B | 4.21B | 32.48% |
| Mar 31, 2024 | 12.96B | 2.93B | 29.17% |
| Mar 31, 2023 | 10.03B | 1.97B | 24.50% |
| Mar 31, 2022 | 8.06B | -79.60M | -0.98% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 83.46B |
| Abbott India | 69.29B |
| Granules India | 53.66B |
| J. B. Chemicals & Pharmaceuticals | 42.08B |
| GlaxoSmithKline Pharmaceuticals | 38.22B |
| Viyash Scientific | 34.20B |
| Caplin Point Laboratories | 21.87B |
| Sanofi India | 17.74B |
AstraZeneca Pharma India News
- 14 hours ago - Why are AstraZeneca Pharma shares down over 4% today? Explained - Business Upturn
- 1 day ago - AstraZeneca Pharma India Quarterly report: Q4 2026 - Filings
- 1 day ago - AstraZeneca Pharma India reports 33% revenue growth for FY 2025-26 - Business Upturn
- 6 days ago - AstraZeneca Pharma India gets CDSCO nod for expanded use of Calquence in Mantle Cell Lymphoma Treatment - Business Upturn
- 7 days ago - AstraZeneca designates key managerial personnel for materiality determination - Business Upturn
- 6 weeks ago - AstraZeneca Pharma India secures approval to market Calquence for new indication - Business Upturn
- 7 weeks ago - AstraZeneca, Telangana govt to roll out AI-powered lung cancer screening in public hospitals - The Times of India
- 2 months ago - AstraZeneca Pharma India appoints Dr. Shashank Srinivasan and promotes Mr. Venkat Natarajan - Business Upturn